Search clinical trials for: Check point inhibitors

Total 69486 results

National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype
D2M Biotherapeutics Inc.

Recruiting

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Advanced Solid Tumor

United States
Jinling Hospital, China
Jiangsu Synthgene Biotechnology Co.Ltd.

Recruiting

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
National Cancer Institute (NCI)

Not yet recruiting

Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
GlaxoSmithKline

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Beijing Hospital
Bethune Charitable Foundation

Recruiting

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Metastatic Colorectal Cancer | MSS | RAS Mutation

China
Hyogo Medical University
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)

Malignant Pleural Mesothelioma

Japan
University Health Network, Toronto

Recruiting

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe)

Cutaneous Melanoma | Mucosal Melanoma | Melanoma Stage IV

Canada
M.D. Anderson Cancer Center

Recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Triple Negative Breast Cancer | Stage 1 cT1b-T1cN0M0

United States
Guangzhou Institute of Respiratory Disease

Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV

China
Amgen

Not yet recruiting

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Chen Xiaoping

Recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC

China
Fudan University

Recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel, United States, Taiwan, Hong Kong, Korea, Republic of, Switzerland, Costa Rica, Malaysia
University Hospital, Grenoble
National Agency for Research on AIDS and Viral Hepatitis (ANRS)

Not yet recruiting

Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination (VITAMIN)

Liver Transplantation | Kidney Transplantation | HBV

France
University of Wisconsin, Madison
National Cancer Institute (NCI); National Institute of Dental and Craniofacial...

Recruiting

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Beijing Friendship Hospital
Changhai Hospital; Peking Union Medical College Hospital; Peking University Cancer...

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Locally Advanced Rectal Cancer

China
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

Australia, United States, Canada, Chile, Taiwan, Argentina
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, New Zealand, Germany, Chile, Australia, United States, Poland, Spain, Sweden, France, Italy
University Medical Center Groningen

Not yet recruiting

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy (PREDICT)

Locally Advanced Rectal Carcinoma

Netherlands
Tongji University

Recruiting

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

Esophageal Cancer

China
Giuseppe Procopio

Not yet recruiting

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT)

Collecting Duct Carcinoma | Renal Medullary Carcinoma | Bellini Carcinoma

Italy
Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Advanced Hepatocellular Carcinoma

China
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Melanoma | Advanced Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Merck Sharp & Dohme LLC
Moderna TX

Recruiting

A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Carcinoma, Squamous Cell | Skin Neoplasms

Chile, Australia, Israel, New Zealand, Spain, France, Norway
Dong-A ST Co., Ltd.

Not yet recruiting

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
University of Alabama at Birmingham

Not yet recruiting

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Hepatocellular Carcinoma

United States
University Hospital, Rouen

Not yet recruiting

Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO> (BELAFENDO)

Kidney Diseases
Melanoma Institute Australia
Bristol-Myers Squibb

Not yet recruiting

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma
M.D. Anderson Cancer Center
Bristol-Myers Squibb; United States Department of Defense; Cancer Prevention...

Not yet recruiting

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Metastatic Renal Cell Carcinoma

United States
RenJi Hospital

Not yet recruiting

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Immune Checkpoint Inhibitors | Clear-cell Metastatic Renal Cell Carcinoma | Cytoreductive Nephrectomy
Duke University

Not yet recruiting

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

GastroEsophageal Cancer

United States
Bio-Thera Solutions

Not yet recruiting

A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Carcinoma, Non-Small-Cell Lung
Peking University People's Hospital

Not yet recruiting

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Myelodysplastic Syndromes | Acute Leukemia | Severe Aplastic Anemia
Jazz Pharmaceuticals

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer | HER2 Gene Mutation

United States, Puerto Rico
Tongji Hospital
Chongqing University Cancer Hospital; Henan Cancer Hospital; Qilu Hospital of... and other collaborators

Not yet recruiting

A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary

Ovarian Clear Cell Carcinoma
Guangzhou University of Traditional Chinese Medicine
Akeso Pharmaceuticals, Inc.

Recruiting

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Non-small Cell Lung Cancer

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection (PENALTY)

Progressive Multifocal Leukoencephalopathy

France
VA Office of Research and Development

Recruiting

Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL)

Non-Small Cell Lung Cancer

United States
Biond Biologics

Not yet recruiting

A Study of BND-35 in Participants With Advanced Solid Tumors

Cancer

Israel
Pliant Therapeutics, Inc.

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor

United States
GeneMedicine Co., Ltd.

Recruiting

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Malignant Melanoma

Korea, Republic of
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Thailand, Slovakia, Argentina, Taiwan, Brazil, Hong Kong
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain, Turkey

3

Subscribe